Ignite Creation Date:
2024-05-06 @ 4:11 PM
Last Modification Date:
2024-10-26 @ 2:05 PM
Study NCT ID:
NCT04897854
Status:
UNKNOWN
Last Update Posted:
2021-05-24
First Post:
2021-05-07
Brief Title:
Timing of Start of systemIc Treatment for Asymptomatic Metastasized Pancreatic Cancer
Sponsor:
Academisch Medisch Centrum - Universiteit van Amsterdam AMC-UvA
Organization:
Academisch Medisch Centrum - Universiteit van Amsterdam AMC-UvA
Study Overview
Official Title:
TIming of Start of systemIc Treatment for Asymptomatic MEtastasized PANcreatic Cancer TIMEPAN a Randomized Controlled Multicenter Trial
Status:
UNKNOWN
Status Verified Date:
2021-05
Last Known Status:
RECRUITING
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
TIMEPAN
Brief Summary:
Since patients with metastatic pancreatic cancer have a limited life expectancy it is important to determine the timing of when to start chemotherapy in order to optimize the benefits of chemotherapy relative to the side effects Therefore two treatment strategies can be considered chemotherapy started immediately at diagnosis or delayed until disease-related symptoms occur
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
False
Is an FDA AA801 Violation?:
None